A French Technology Transfer Office offers a new compound for the treatment of diabetes
A French Technology Transfer Office (TTO) offers a new compound for the treatment of glucose intolerance and more precisely for the treatment of the diabetes thanks to the administration of a known molecule at a lower dosage. This new technology targets the market of drugs dealing with metabolic disorders. The French TTO is looking for interested pharmaceutical corporations or biotechnology SMEs for a licensing agreement or for a technical cooperation agreement.
The partner sought could be a large corporate, medium-sized company or start-up operating in pharmaceutical, drug design or biotechnology development. More precisely, the TTO targets companies involved in the field of metabolic disorders interested in developing some more efficient therapeutic solutions for diabetes and obesity. A licensing agreement is open to pharmaceutical or biotech companies in case of further needed development to meet industrial and clinical challenges to commercialize drugs. A technical cooperation agreement is open to manufacturing drugs firms which are able to drive pre-clinical and clinical testing of the new compound.
A French Technology Transfer Office (TTO) acting on behalf major life science research labs in Paris Region, has developed a new compound for glucose intolerance. Conditions related to glucose intolerance are all characterized by impaired insulin and glucose metabolism. These kinds of intolerance cause serious damage such as liver fibrosis and abnormal fat liver content. Diabetes represents high levels of blood sugar over a long period. Therapies available for advanced stages of diabetes mainly consist in insulin injection which presents important adverse effects such as weight gain or insulin resistance. Accordingly, there is still a need for safer and more effective treatments for metabolic disorders. Researchers from the French university have observed that p-cresol, known as a toxic molecule at high concentration, is able to enhance insulin secretion cells proliferation in mice at 0.5mg/kg without toxic effect. Indeed, the administration of non-toxic doses of this compound in preclinical models of diabetes is associated with reduced body weight and adiposity, improved glucose tolerance and enhanced glucose-stimulated insulin secretion in vivo. The partner sought could be a company interested in: - a technical cooperation agreement to analyse the preclinical results of this new compound and launch clinical trials, - a license agreement in order to commercialize the technology. The TTO is ready to negotiate directly the patent rights transactions for specific applications.
Advantages and innovations
Compared to existing treatments such as insulin injection which induces adverse effects, the proposed new compound shows the following advantages: - reduction of adiposity and body weight (10 to 15% less weight) - reduction of glucose in blood (15 to 20%) - reduction of liver fibrosis - improvement of glucose tolerance - increase of glucose-stimulated insulin secretion - increase of pancreatic islet density - no toxicity at therapeutic doses in vivo This new treatment is significant because no adverse clinical signs were observed.
Under development/lab tested
Intellectual Property Rights (IPR)
Patent(s) applied for but not yet granted
Register your interest
How it works
- Tell us about yourself
- We’ll discuss with you
- We put the right partners in touch
EEN help you find the right partner, rather than you going it alone.
Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.
These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.
Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.
First we need to check you’re human.
Thank you for verifying your email. We have sent you a confirmation email containing a 6 digit verification code to unlock the form below